Under the Paperwork Reduction Act of 1995, no pens to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10825086		
Filing Date		2004-04-15		
First Named Inventor Shin		MATSUDA et al.		
Art Unit		1743		
Examiner Name	Alexa	nder, Lyle		
Attorney Docket Number		81716.0123		

			U.S.PATENTS						Remove		
		Kind Code ¹				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1	4222671		1980-09	3-16	Gilmore					
	2	6136272	A	2000-10	1-24	Weigl et al.					
	3	6190034	B1	2001-02	2-20	Nielson et al.			oonds to Japar tion number 11		shec
If you wis	h to a	d additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Cite No Publication Number		Publication Number	Kind Publication Code ¹ Date		Name of Pate of cited Docu	entee or Applicant iment	Releva	Columns,Lin ant Passages s Appear			
	1										
If you wish	h to a	dd additional U.S. Publi		·				d button			
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Colum where Releva Passages or I Figures Appe	nt Relevant ar	тя
	1	11512645	JP		A	1999-11-02	Danfoss A/S		Corresponds to patent number and WO publish application num 9712665	6190034 hed	×

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10825086		
Filing Date		2004-04-15		
First Named Inventor Shin I		MATSUDA et al.		
Art Unit		1743		
Examiner Name Alexa		nder, Lyle		
Attorney Docket Number		81716 0123		

	2	9712665	wo)	A1	1997-04-10	Danfoss A/	s	Corresponds to Japanese published application number 11512645	
If you wis	h to a	dd additiona	l Foreign Pater	nt Document	citation	information pl	ease click t	he Add butto	n Add	
				NON-PATEN	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Тs				
	Japanese language pretrial reexamination report and its partial English translation list the references above							×		
If you wish	h to a	dd additiona	l non-patent lite	erature docur	ment cit	tation informat	on please	lick the Add	button Add	
EXAMINER SIGNATURE										
Examiner	Signa	ture					Date (Considered		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

See Knd Code of USPTO Petent Documents at Invest (ISPTO, DOLL) or MPEP 96164. * Enter of this that issued the document, by the Involved (WIPO) Standard 513.) * For implanees petent counters, the included on the year of the register or imprecede the serial review of the pathet document.

Kind of counters by the appropriate symbols as indicated on the document under WIPO Standard 511.6 if possible. **Applicant is to place a check mark here if Engine Interquate Persistence in settlement.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10825086	
Filing Date		2004-04-15	
First Named Inventor	Shin I	MATSUDA et al.	
Art Unit		1743	
Examiner Name	Alexa	nder, Lyle	
Attorney Docket Number		81716.0123	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
X	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information displacate statement. Con 27 CER 1 07(a)/1)

OR

	That no item of information contained in the information disclosure statement was cited in a communication from a
	foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
	after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
]	any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure

		aubmitted berewith

-

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

lorin or the signature.	offit of the signature.								
Signature	/tms/	Date (YYYY-MM-DD)	2007-08-30						
Name/Print	Troy M. Schmelzer	Registration Number	36667						

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.